Elsa Abranches | Chief Scientific Officer
ViSync Technologies

Elsa Abranches is currently the Chief Scientific Officer of  ViSync Technologies S.A., Portugal, where she leads the scientific, research, and technological operations, guiding
the development of new platforms in the field of viral and cell ATMPs (Advanced Therapy Medicinal products) formulation and drug delivery. Elsa is currently also the regional treasurer of the European Committee of the International Society for Cell and Gene Therapy (ISCT).  Elsa joined ViSync Technologies coming from AstraZeneca, where she led a section providing translational technology and high-quality cells for pre-clinical research, to enable the
efficient development and delivery of Cell Therapies to patients. Before that, Elsa worked at the UK Regulator (Medicines and Healthcare products Regulatory Agency, MHRA), heading of the Division of Advanced Therapies and also being the director of the UK Stem Cell Bank, focusing on the delivery of a program for cell and gene therapy standardization.
Elsa Abranches is internationally recognized for her expertise in stem cell biotechnology, standardization and Advanced Therapies regulation areas, with over 20 years of experience
ranging from applied research through to manufacturing and regulatory compliance of stem cell-derived products. Elsa has received her degree in Chemical Engineering in 2001 and her Ph.D in Stem Cell Biotechnology in 2006, from the Technical University of Lisbon. Since then, Elsa has
delivered on multiple collaborative projects with Academia, Industry and Regulatory bodies, and has been involved in several national and international committees supporting regulatory compliance and delivery of ATMPs.